Hapuarachchi SV , Cobbold SA , Shafik SH , Dennis AS , McConville MJ , Martin RE , Kirk K , Lehane AM .

	Fig 1. Representative traces illustrating the strategy employed to screen the Malaria Box for compounds that perturb the cytosolic pH (pHcyt) of the parasite.Malaria Box compounds (1 μM; from the May 2012 Malaria Box batch; identified here by their positions on the plates) were added successively to BCECF-loaded isolated 3D7 P. falciparum trophozoites (suspended at 37°C in pH 7.10 Experimental Saline Solution). A maximum of nine inactive compounds were tested on a single batch of parasites before the V-type H+-ATPase inhibitor concanamycin A (conA; 100 nM) was added as a positive control to ensure that a pH change was still detectable (A). A batch of parasites was also replaced with a new batch after a hit was detected (B) or a compound caused an optical effect (seen as an instantaneous perturbation of the fluorescence signal; C). In the latter case concanamycin A (100 nM) was added before changing to another batch of parasites. The purpose of adding the concanamycin A was to confirm (or otherwise) that any such optical effect did not obscure the pH-responsiveness of the fluorescence signal.
	Fig 2. Fluorescence traces showing the effects of DMSO (solvent control), MMV007839 and MMV000972 on the cytosolic pH (pHcyt) of 3D7 P. falciparum trophozoites under varying conditions.Each trace is representative of those obtained in at least three independent experiments. (A-C) The effects of DMSO (0.1% v/v; solvent control; A), MMV007839 (1 μM; B) and MMV000972 (1 μM; C) on the cytosolic pH of parasites suspended in (glucose-containing) Experimental Saline Solution (pH 7.10) at 37°C. (D-F) The effects of DMSO (0.25% v/v; solvent control; D), MMV007839 (2.5 μM; E), and MMV000972 (2.5 μM; F) on the cytosolic pH of parasites suspended (for 10 min prior to commencing recording, and throughout the initial recording period) in glucose-free Experimental Saline Solution (pH 7.10, 37°C), and the effects of the subsequent addition of glucose (22 mM) to the parasite suspension. (G-I) The effects of adding DMSO (0.25% v/v; solvent control; G), MMV007839 (2.5 μM; H), and MMV000972 (2.5 μM; I), followed by sodium L-lactate (10 mM), on the cytosolic pH of parasites suspended at 4°C in Experimental Saline Solution (pH 7.10).
	Fig 3. L-[14C]lactate influx into PfFNTGly107Ser mutant parasites and Dd2 parental parasites.(A) The uptake of L-[14C]lactate by isolated trophozoite-stage PfFNTGly107Ser mutant parasites (white bars) and Dd2 parental parasites (black bars) in the absence of compound (0.4% v/v DMSO; solvent control) and in the presence of the non-specific anion transport inhibitor NPPB (100 μM). The mean distribution ratio (i.e., [intracellular L-[14C]lactate]/[extracellular L-[14C]lactate]) and SEM from nine (parent) or seven (mutant) independent experiments for the control, and from three independent experiments for NPPB, are shown. The results of unpaired t-tests are shown; ***P < 0.001. (B-C) The effects of MMV007839 (B) and MMV000972 (C) on L-[14C]lactate uptake into isolated trophozoite-stage PfFNTGly107Ser mutant parasites (white symbols) and Dd2 parental parasites (black symbols). L-[14C]lactate uptake in the presence of each concentration of MMV compound is expressed as a percentage of that observed when there was no inhibition of transport. The data shown are the average ± SEM from n independent experiments performed on different days, where n was seven for the MMV007839 data with parental parasites, three for the MMV007839 data with PfFNTGly107Ser mutant parasites, three for the MMV000972 data with parental parasites, and four for the MMV000972 data with PfFNTGly107Ser mutant parasites (with the exception of the lowest concentration, for which there was one less experiment in all cases). In all cases (panels A-C), the experiments were performed at 4°C in pH 6.1 Experimental Saline Solution, and parasites were preincubated with the compound (at the concentration indicated) or DMSO (0.4% v/v; solvent control) for 1 min prior to the addition of L-[14C]lactate (1.3 μM). The concentrations of compound and DMSO after the addition of L-[14C]lactate were the same as those present during the preincubation. The uptake of L-[14C]lactate was measured over 20 s.
	Fig 4. The effects of MMV007839 and MMV000972 on PfFNT-mediated L-[14C]lactate uptake by Xenopus oocytes expressing native PfFNT or PfFNTGly107Ser.The PfFNT-mediated uptake of L-[14C]lactate by oocytes expressing native PfFNT (black symbols) or oocytes expressing PfFNTGly107Ser (white symbols) was measured in the presence of a range of different concentrations of MMV007839 (A) and MMV000972 (B). The component of transport attributable to PfFNT (or to PfFNTGly107Ser) was determined by subtracting the uptake of L-[14C]lactate into non-injected oocytes (averaged from the values obtained across the full range of inhibitor concentrations tested, noting that the uptake of L-[14C]lactate into non-injected oocytes was unaffected by either inhibitor; S4 Fig) from the uptake of L-[14C]lactate measured (at each inhibitor concentration) into oocytes expressing either native PfFNT or PfFNTGly107Ser. In all panels, the PfFNT-mediated uptake of L-[14C]lactate is expressed as a percentage of that determined for native PfFNT in the absence of MMV compound (0.4% v/v DMSO; solvent control). To enable a visual comparison between the native PfFNT and PfFNTGly107Ser datasets, only part of the concentration range used for the latter is shown in the main panels. The insets show the data obtained for PfFNTGly107Ser over the full concentration range tested. In all cases, the data are averaged from four independent experiments (using oocytes from different frogs) and are shown ± SEM. The uptake was measured at 27.5°C over 10 min at pH 6.4 using 2.7 μM L-[14C]lactate and 600 μM unlabelled L-lactate.
	Fig 5. The effect of MMV007839 on the metabolite profile of parasitised erythrocytes.(A) Relative amounts of intracellular metabolites in MMV007839-treated parasitised erythrocytes (infected with the 3D7 strain) and untreated parasitised erythrocytes. The data shown are the mean log2 ratios of the level of each metabolite in the MMV007839-treated samples relative to its level in the untreated samples (+ MMV007839/- MMV007839), determined 1 h, 3 h and 6 h after the addition of MMV007839, obtained from three independent experiments. The concentration of MMV007839 used (6 μM) corresponds to approximately 20× the IC50 value for growth inhibition of 3D7 parasites. (B) The log2 ratios of metabolite levels in MMV007839-treated samples relative to those in untreated samples for all metabolites of known identity for which a statistically significant difference in abundance was observed between MMV007839-treated and untreated infected erythrocytes (see S1 Data for statistical analysis). The data shown are the mean + SEM from three independent experiments. GL3P, sn-glycerol-3-phosphate; Pyr, pyruvate; Lac, lactate; R5P, ribose-5-phosphate; AcCoA, acetyl coenzyme A; Gln, glutamine; VD, Val-Asp; PE, Pro-Glu; PVQ, Pro-Val-Gln; PDAV, Pro-Asp-Ala-Val; TNVK, Thr-Asn-Val-Lys; Oro, orotate; O5P, orotidine-5-phosphate; DC, deoxycytidine; GGPP, geranylgeranyl-pyrophosphate. (C) Relative amounts of metabolites in the extracellular medium in suspensions containing MMV007839-treated and untreated parasitised erythrocytes. The data shown are the mean log2 ratios (+ MMV007839/- MMV007839) + SEM from three independent experiments. There was a statistically significant difference in the concentrations of 3-phosphoglycerate and phosphoenolpyruvate in the extracellular medium between MMV007839-treated and untreated cell suspensions (see S1 Data). DHAP, glycerone phosphate; PEP, phosphoenolpyruvate; 3PG, 3-phosphoglycerate; Cit, citrate; αKG, 2-ketoglutarate; Mal, malate; Pip, pipecolate.
	Fig 6. The effect of MMV007839 on the volume of parasites and parasitised erythrocytes.MMV007839 (1 μM) and DMSO (0.1% v/v; solvent control) were tested for their effects on the volume of (A) saponin-isolated 3D7 P. falciparum trophozoites suspended at 37°C in pH 7.10 Experimental Saline Solution and (B) intact erythrocytes infected with 3D7 trophozoites suspended at 37°C in a pH 7.40 bicarbonate-free RPMI medium (containing supplements as outlined in the Materials and Methods). The data are expressed as a percentage volume increase relative to the starting volume, which for isolated parasites (A) ranged from 35 fL to 46 fL in the individual experiments, and for intact infected erythrocytes (B) ranged from 73 fL to 79 fL. In both cases the data shown are the mean ± SEM from three independent experiments performed on different days. For each condition, the (pre-normalised) volume data for each time point greater than 0 was tested for statistical significance compared to the time zero data for that condition; **P < 0.01, ***P < 0.001.

Adjalley, A method for rapid genetic integration into Plasmodium falciparum utilizing mycobacteriophage Bxb1 integrase. 2010, Pubmed

Adjalley, A method for rapid genetic integration into Plasmodium falciparum utilizing mycobacteriophage Bxb1 integrase. 2010, Pubmed
Allen, Plasmodium falciparum culture: the benefits of shaking. 2010, Pubmed
Allen, The membrane potential of the intraerythrocytic malaria parasite Plasmodium falciparum. 2004, Pubmed
Baragaña, A novel multiple-stage antimalarial agent that inhibits protein synthesis. 2015, Pubmed
Carter, Isolation and functional characterization of the PfNT1 nucleoside transporter gene from Plasmodium falciparum. 2000, Pubmed , Xenbase
Clasquin, LC-MS data processing with MAVEN: a metabolomic analysis and visualization engine. 2012, Pubmed
Cobbold, Metabolic Dysregulation Induced in Plasmodium falciparum by Dihydroartemisinin and Other Front-Line Antimalarial Drugs. 2016, Pubmed
Corey, A broad analysis of resistance development in the malaria parasite. 2016, Pubmed
Cui, Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network. 2015, Pubmed
Ding, A framework for assessing the risk of resistance for anti-malarials in development. 2012, Pubmed
Downie, Transport of nucleosides across the Plasmodium falciparum parasite plasma membrane has characteristics of PfENT1. 2006, Pubmed , Xenbase
Elliott, Transport of lactate and pyruvate in the intraerythrocytic malaria parasite, Plasmodium falciparum. 2001, Pubmed
Gamo, Thousands of chemical starting points for antimalarial lead identification. 2010, Pubmed
Guiguemde, Chemical genetics of Plasmodium falciparum. 2010, Pubmed
Hayward, The pH of the digestive vacuole of Plasmodium falciparum is not associated with chloroquine resistance. 2006, Pubmed
Holm-Bertelsen, High-level cell-free production of the malarial lactate transporter PfFNT as a basis for crystallization trials and directional transport studies. 2016, Pubmed
Jiménez-Díaz, (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. 2014, Pubmed
Joet, Validation of the hexose transporter of Plasmodium falciparum as a novel drug target. 2003, Pubmed , Xenbase
Klonis, Evaluation of pH during cytostomal endocytosis and vacuolar catabolism of haemoglobin in Plasmodium falciparum. 2007, Pubmed
Kuhn, Quantitative pH measurements in Plasmodium falciparum-infected erythrocytes using pHluorin. 2007, Pubmed
Lambros, Synchronization of Plasmodium falciparum erythrocytic stages in culture. 1979, Pubmed
Lehane, Diverse chemotypes disrupt ion homeostasis in the Malaria parasite. 2014, Pubmed
Lehane, A verapamil-sensitive chloroquine-associated H+ leak from the digestive vacuole in chloroquine-resistant malaria parasites. 2008, Pubmed
Lehane, Efflux of a range of antimalarial drugs and 'chloroquine resistance reversers' from the digestive vacuole in malaria parasites with mutant PfCRT. 2010, Pubmed
MacRae, Mitochondrial metabolism of sexual and asexual blood stages of the malaria parasite Plasmodium falciparum. 2013, Pubmed
malERA Consultative Group on Drugs, A research agenda for malaria eradication: drugs. 2011, Pubmed
Marchetti, A lactate and formate transporter in the intraerythrocytic malaria parasite, Plasmodium falciparum. 2015, Pubmed , Xenbase
Martin, Chloroquine transport via the malaria parasite's chloroquine resistance transporter. 2009, Pubmed , Xenbase
Mehta, Malaria parasite-infected erythrocytes inhibit glucose utilization in uninfected red cells. 2005, Pubmed
Ortiz, Identification of Selective Inhibitors of the Plasmodium falciparum Hexose Transporter PfHT by Screening Focused Libraries of Anti-Malarial Compounds. 2015, Pubmed
Parker, Identification of a nucleoside/nucleobase transporter from Plasmodium falciparum, a novel target for anti-malarial chemotherapy. 2000, Pubmed , Xenbase
Patel, New antimalarial targets: the example of glucose transport. 2008, Pubmed
Paul, Separation of malaria-infected erythrocytes from whole blood: use of a selective high-gradient magnetic separation technique. 1981, Pubmed
Plouffe, In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. 2008, Pubmed
Richards, Molecular Mechanisms for Drug Hypersensitivity Induced by the Malaria Parasite's Chloroquine Resistance Transporter. 2016, Pubmed , Xenbase
Rottmann, Spiroindolones, a potent compound class for the treatment of malaria. 2010, Pubmed
Saliba, Sodium-dependent uptake of inorganic phosphate by the intracellular malaria parasite. 2006, Pubmed , Xenbase
Saliba, Transport and metabolism of the essential vitamin pantothenic acid in human erythrocytes infected with the malaria parasite Plasmodium falciparum. 1998, Pubmed
Saliba, pH regulation in the intracellular malaria parasite, Plasmodium falciparum. H(+) extrusion via a V-type H(+)-ATPase. 1999, Pubmed
Smilkstein, Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. 2004, Pubmed
Spangenberg, The open access malaria box: a drug discovery catalyst for neglected diseases. 2013, Pubmed
Spillman, The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs. 2015, Pubmed
Spillman, Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. 2013, Pubmed
Spry, Pantothenamides are potent, on-target inhibitors of Plasmodium falciparum growth when serum pantetheinase is inactivated. 2013, Pubmed
Staalsoe, Detection of antibodies to variant antigens on Plasmodium falciparum-infected erythrocytes by flow cytometry. 1999, Pubmed
Trager, Human malaria parasites in continuous culture. 1976, Pubmed
Vaidya, Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum. 2014, Pubmed
van Schalkwyk, Verapamil-Sensitive Transport of Quinacrine and Methylene Blue via the Plasmodium falciparum Chloroquine Resistance Transporter Reduces the Parasite's Susceptibility to these Tricyclic Drugs. 2016, Pubmed , Xenbase
van Schalkwyk, Inhibition of Plasmodium falciparum pH regulation by small molecule indole derivatives results in rapid parasite death. 2010, Pubmed
Van Voorhis, Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond. 2016, Pubmed
Wells, Malaria medicines: a glass half full? 2015, Pubmed
Wu, Identity of a Plasmodium lactate/H(+) symporter structurally unrelated to human transporters. 2015, Pubmed
Xia, MetaboAnalyst 3.0--making metabolomics more meaningful. 2015, Pubmed